According to previous studies, NKILA combines with NF‐κB: IκB complex and directly mask the phosphorylation site of IκB from IKK, thereby inhibiting IKK‐induced IκB phosphorylation and degradation, finally inhibiting the activation of NF‐κB signaling in breast cancer 15, nonsmall cell lung cancer 17, and tongue squamous cell carcinoma 18. The gene discussed is NFKB1; the disease is breast cancer.